Brief: Aevitas Therapeutics, A Fortress Biotech Subsidiary, Announces Asset Purchase Agreement With 4D Molecular Therapeutics For World-Wide Rights To Aevitas’ Short-Form Human Complement Factor H

4D Molecular Therapeutics

24/04/2023 13:37

April 24 (Reuters) - AEVITAS THERAPEUTICS:
    * AEVITAS THERAPEUTICS, A FORTRESS BIOTECH SUBSIDIARY,
ANNOUNCES
ASSET PURCHASE AGREEMENT WITH 4D MOLECULAR THERAPEUTICS FOR
WORLD-WIDE RIGHTS TO AEVITAS’ SHORT-FORM HUMAN COMPLEMENT FACTOR
H
    * AEVITAS THERAPEUTICS - 4DMT TO MAKE CASH PAYMENTS TO CO
TOTALING
UP TO ABOUT $140 MILLION IN POTENTIAL LATE-STAGE DEVELOPMENT,
REGULATORY, SALES MILESTONES
    * AEVITAS THERAPEUTICS - RANGE OF SINGLE-DIGIT ROYALTIES ON
NET
SALES ARE ALSO PAYABLE UNDER TERMS OF AGREEMENT

Source text for Eikon:  ID:nGNXDTbcd 
Further company coverage:  FDMT.O 

 ((Reuters.Briefs@thomsonreuters.com;))